Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Addis Ababa WeeklyAddis Ababa Weekly
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Addis Ababa WeeklyAddis Ababa Weekly
    Home » Spravato becomes first FDA-approved standalone depression treatment
    Health

    Spravato becomes first FDA-approved standalone depression treatment

    January 22, 2025
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email

    The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s nasal spray, Spravato, as a standalone treatment for adults with major depressive disorder (MDD) that is resistant to conventional therapies. This marks a significant development in the treatment of depression, as Spravato becomes the first FDA-approved standalone therapy for treatment-resistant depression (TRD). The decision reflects the growing acceptance of the drug, which recorded $780 million in sales in the first nine months of 2024.

    Spravato becomes first FDA-approved standalone depression treatment
    Image used for illustrative purposes only.

    Spravato, which entered the U.S. market in 2019, was previously approved for use alongside oral antidepressants to treat TRD and acute suicidal ideation in MDD patients. This new approval allows it to be administered without oral antidepressants, providing a vital option for patients whose symptoms do not improve with traditional treatments or who experience adverse effects like weight gain and sexual dysfunction.

    The decision is based on data from a phase four clinical trial showing that Spravato alone can improve depressive symptoms as quickly as 24 hours after administration, with effects lasting at least a month. Johnson & Johnson stated that the drug’s safety profile in the standalone trial aligned with prior findings from its combination use with oral antidepressants. Dr. Gregory Mattingly, president of the Midwest Research Group and a participant in Spravato’s clinical trials, emphasized the transformative potential of this treatment.

    His St. Louis facility, one of 3,000 certified outpatient centers in the U.S., has treated over 6,000 patients with Spravato, offering hope to those who have struggled with inadequate responses to other medications. Spravato’s active ingredient, esketamine, is derived from ketamine, an anesthetic known for its rapid action in the brain. The nasal spray enables faster symptom relief compared to traditional oral antidepressants, which often take weeks to demonstrate efficacy.

    However, its potential risks, including sedation, dissociation, and misuse, necessitate strict monitoring. Patients must be supervised for two hours after administration in certified healthcare settings, as the drug is not available for pharmacy purchase. Johnson & Johnson anticipates Spravato becoming a blockbuster product, projecting annual sales between $1 billion and $5 billion. This growth could offset potential challenges from patent expirations and Medicare price negotiations affecting its top-selling drug, Stelara.

    The approval underscores the importance of personalized approaches in mental health treatment. Bill Martin, J&J’s global head of neuroscience, highlighted how this new option enables patients and caregivers to tailor treatment plans effectively. With increased physician familiarity and real-world data supporting its efficacy, Spravato is poised to redefine management strategies for treatment-resistant depression. Spravato’s trajectory reflects growing confidence within the medical community. As mental health care evolves, this FDA approval represents a critical step in addressing the unmet needs of millions living with depression. – By MENA Newswire News Desk.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email

    Related Posts

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026

    Ebola deaths in DR Congo reach 5,340, fatality rate at 51.6%

    November 2, 2026

    Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

    October 28, 2026
    Latest News

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026

    Damascus becomes Air Arabia Dammam’s second foreign route

    November 17, 2026
    © 2026 Addis Ababa Weekly | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.